GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » SC Ropharma SA (BSE:RPH) » Definitions » EV-to-EBITDA

SC Ropharma (BSE:RPH) EV-to-EBITDA : 5.35 (As of May. 26, 2024)


View and export this data going back to 1997. Start your Free Trial

What is SC Ropharma EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, SC Ropharma's enterprise value is lei246 Mil. SC Ropharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was lei46 Mil. Therefore, SC Ropharma's EV-to-EBITDA for today is 5.35.

The historical rank and industry rank for SC Ropharma's EV-to-EBITDA or its related term are showing as below:

BSE:RPH' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.51   Med: 8.59   Max: 13.43
Current: 5.35

During the past 13 years, the highest EV-to-EBITDA of SC Ropharma was 13.43. The lowest was 4.51. And the median was 8.59.

BSE:RPH's EV-to-EBITDA is ranked better than
86.48% of 466 companies
in the Healthcare Providers & Services industry
Industry Median: 12.715 vs BSE:RPH: 5.35

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-26), SC Ropharma's stock price is lei0.192. SC Ropharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was lei0.015. Therefore, SC Ropharma's PE Ratio for today is 12.80.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


SC Ropharma EV-to-EBITDA Historical Data

The historical data trend for SC Ropharma's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SC Ropharma EV-to-EBITDA Chart

SC Ropharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.07 6.37 4.87 6.13 5.70

SC Ropharma Semi-Annual Data
Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.87 5.19 6.13 42.72 5.70

Competitive Comparison of SC Ropharma's EV-to-EBITDA

For the Pharmaceutical Retailers subindustry, SC Ropharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SC Ropharma's EV-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, SC Ropharma's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where SC Ropharma's EV-to-EBITDA falls into.



SC Ropharma EV-to-EBITDA Calculation

SC Ropharma's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=245.730/45.901
=5.35

SC Ropharma's current Enterprise Value is lei246 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SC Ropharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was lei46 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SC Ropharma  (BSE:RPH) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

SC Ropharma's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.192/0.015
=12.80

SC Ropharma's share price for today is lei0.192.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SC Ropharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was lei0.015.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


SC Ropharma EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of SC Ropharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


SC Ropharma (BSE:RPH) Business Description

Traded in Other Exchanges
N/A
Address
Str. Iuliu Maniu Nr. 55, ETAJ 1, Brasow, ROU, 500091
SC Ropharma SA is engaged in the production, distribution, and Retail sale of pharmaceutical products in specialized stores. Its product portfolio comprises over 50 products in the form of tablets, powders, capsules, and syrups covering 21 therapeutic areas.

SC Ropharma (BSE:RPH) Headlines

No Headlines